The combination of KRASG12Di MRTX1133 and immune checkpoint inhibitors can activate the FAS pathway, continuously inhibit tumor growth, enhance the ability to clear cancer cells, and improve survival outcomes (48). This evidence concerns the gene FAS and neoplasm.